All GLG News Analyses Filed Under: Oncology

Has Avastin "hit the wall" as far as increased sales are concerned? Growth in the breast cancer market has not been as exuberant as expected.

O  "Biosimilars," or generic versions of biological drugs, are possible -- and are coming -- but scientific considerations must dictate the extent and kind of testing that is required, and the criteria for approval by regulators.  O  The drug described in the source article is less...

An indian product similar to Amgen's Filgastrim " G-CSF" showed comparable efficacy and safety in a trial in Europe and is expected to get EMEA approval in 2010.  " Neukine" is already in use in India and in several "developing countries" in the MiddlE Esat and Asia where it is available at less...

Antigenics' Oncophage is a form of immunotherapy for patients with intermediate risk renal cancer that showed efficacy in improving recurrence free survival in a randomized trial . The approval in Russia, may be due in addition to the obvious reason of less regulatory restrictions, is that the company...

This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!

Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???

This drug, which has just entered Phase I testing, is very interesting because it combines IL-12, which has shown both activity and significant toxicity, with a targeting antibody. Hopefully, this targeting antibody will minimize the toxicity of IL-12 on or in normal tissues.

The failure of this study has wide ranging implications for Pfizer and other melanoma trials. This drug, which only a few years ago caused much excitement in the melanoma oncology community, failed to show any survival benefit in this Phase III trial, when compared to standard, but generally ineffective,...

While disappointing for patients and caregivers, Pfizer's loss of a late-stage treatment for melanoma casts an even darker shadow on the ability of pharmaceutical and biotech companies to successfully bring new treatments to market. Coupled with other recent Phase 3 failures, this latest outcome points...

This article is briefly stating the future hold of Pfizer in developing drugs for cancer treatment. The infomation provided is incompleted, for example, there is an absence of detailed information on the phase III clinical trial neccesary to know if there is a flaw in the...